Lakeshore Hospital and Research Centre Unlisted Share Price Today
ISIN INE01TI01010.
About Company Lakeshore Hospital and Research Centre is a leading multi-specialty tertiary care hospital in Kerala. The hospital provides comprehensive healthcare services across key specialties including cardiology, neurology, oncology, nephrology, orthopedics, gastroenterology, and critical care. Its revenue mix is primarily derived from inpatient services, outpatient consultations, diagnostic services, surgical procedures, and allied healthcare offerings, with a strong focus on tertiary an…
Lakeshore Hospital and Research Centre
Lakeshore Hospital and Research Centre Unlisted Share Price Today
About Company
Lakeshore Hospital and Research Centre is a leading multi-specialty tertiary care hospital in Kerala. The hospital provides comprehensive healthcare services across key specialties including cardiology, neurology, oncology, nephrology, orthopedics, gastroenterology, and critical care. Its revenue mix is primarily derived from inpatient services, outpatient consultations, diagnostic services, surgical procedures, and allied healthcare offerings, with a strong focus on tertiary and quaternary care.
Lakeshore follows an asset-heavy, infrastructure-driven operating model, with significant investments in hospital buildings, advanced medical equipment, and clinical technology. The company emphasizes specialty-led care, high clinical standards, and service differentiation, rather than aggressive multi-city expansion. Its performance is closely linked to occupancy rates, case mix intensity, pricing power, insurance penetration, and medical tourism inflows, making operating leverage and asset utilisation key drivers of profitability.
Based in Kochi, Kerala, Lakeshore primarily caters to patients across Kerala and neighboring states, while also benefiting from inbound medical tourism demand.
EBITDA margin improved from 13.91% (FY21) to a peak of 25.57% (FY23).
PAT declined from ₹57.51 Cr (FY23) to ₹39.11 Cr (FY25).
After a sharp rebound in FY22-FY23, revenue growth has moderated to 2.85% in FY25.
